Loading
Journal of Cancer Biology
ISSN: 2692-7896
Volume 7, Issue 1, p1-18
Articles published in this issue are Open Access and licensed under Creative Commons Attribution License (CC BY NC) where the readers can reuse, download, distribute the article in whole or part by mentioning proper credits to the authors.
Exercise and its influence on the tumor microenvironment — the role of muscle-cancer cross talk
Exercise is increasingly being recognized as an important part of cancer treatment, as it has been shown to alleviate treatment- and disease-related side effects and improve quality of life of patients with cancer. Furthermore, exercise has been linked to a reduced risk of cancer recurrence, particularly in cases of breast and colorectal cancer. In recent years, the question has come to the forefront: “How?” does exercise influences cancer survival, and with it the interest in the underlying physiological mechanisms.
J Cancer Biol, 2026, Volume 7, Issue 1, p1-2 | DOI: 10.46439/cancerbiology.7.081
Wearable device for detection and elimination of cancer cells at inception: birth of a new era
Despite major advances in molecular oncology and cancer therapeutics, early detection remains a critical limitation for many malignancies. Current screening approaches rely largely on anatomical or morphological changes, highlighting a persistent gap between modern biological understanding of cancer and its clinical application. This article examines the evolution of cancer biology and explores why these advances have not yet translated into effective early detection strategies.
J Cancer Biol, 2026, Volume 7, Issue 1, p3-6 | DOI: 10.46439/cancerbiology.7.082
Molecular subtypes of breast cancer in Nigeria: clinicopathological insights from immunohistochemical profiling
Breast cancer remains the most frequently diagnosed malignancy among women worldwide and a leading cause of cancer-related mortality. Its burden continues to rise in low- and middle-income countries, where late presentation, limited diagnostic capacity, and uneven access to targeted therapies contribute substantially to poor outcomes.
J Cancer Biol, 2026, Volume 7, Issue 1, p7-14 | DOI: 10.46439/cancerbiology.7.083
Preoperative radiation boost in early-stage breast cancer: a focused report
In breast-conserving therapy, whole-breast radiotherapy (WBRT) followed by a postoperative tumor bed boost is the standard approach for patients at increased risk of local recurrence [1–6]. However, postoperative boost delivery is limited by challenges in tumor bed delineation after surgery, particularly in the setting of oncoplastic reconstruction, and may prolong overall locoregional treatment time. Historical concerns regarding wound healing have limited the use of preoperative breast radiotherapy, though these concerns largely stem from experiences with whole-breast irradiation rather than limited-volume boost dosing [7,8].
J Cancer Biol, 2026, Volume 7, Issue 1, p15-18 | DOI: 10.46439/cancerbiology.7.084
Fight tumor heterogeneity
Intratumor heterogeneity has attracted more and more attention in recent years. Heterogeneity is the driving force of tumor clone evolution. Chromosomal instability, somatic mutation, epigenetic modification and extrachromosomal DNA (ecDNA) contribute to tumor heterogeneity. The degree of such heterogeneity is extremely high.
Modulating the immunotolerant tumor microenvironment to enhance irreversible electroporation ablation therapy
Over the years, several ablation techniques, such as radiofrequency ablation (RFA), microwave ablation, and cryoablation, have been developed and implemented in the treatment of different cancers. Of these ablation technologies, RFA is the most widely used. RFA is a form of thermal ablation that relies on radio waves to produce an electrical current at the tip of an inserted electrode, thus allowing for heat production at the site of the tumor.
Harnessing innovation for the future of breast cancer management
Background: Breast cancer remains a major global health burden despite therapeutic advances, necessitating further innovations to address persistent challenges like therapeutic resistance, adverse effects, and mortality in subgroups. Emerging technologies offer promising opportunities in this regard through data-driven, precise, and personalized approaches.
A scoping review of outcome measures in ovarian cancer clinical trials
The incorporation of patient-reported outcomes (PROs) is essential for assessing whether a cancer treatment enhances overall patient well-being, beyond merely extending survival. This scoping review aimed to identify and analyze the use of PROs in ovarian cancer clinical trials.
Significance of BRCA genetic testing for preoperative breast cancer patients
Examining BRCA mutations in preoperative breast cancer patients is very important when selecting a surgical procedure. Although there are advantages and disadvantages associated with knowing about the presence of genetic mutations, including for the patient’s family, there are many benefits for the patient. BRCA genetic testing should be recommended for patients who are strongly suspected of being positive for a BRCA mutation.
Molecular signatures of aggressive pediatric liver cancer
Liver masses account for 5 to 6% of pediatric cancer, which includes hepatoblastoma (HBL) along with rare cases of hepatocellular carcinoma (HCC). The most dangerous form of pediatric liver cancer is aggressive HBL, which can be characterized by chemo-resistance and multiple nodules or metastases at diagnosis, all correlating with worse clinical prognosis. Despite intensive studies and a significant improvement in overall outcomes, very little is known about the key molecular pathways which determine the aggressiveness of pediatric liver cancer.
Deregulation of Slug/Snail2 and TGF-β crosstalk in airway epithelial stem/progenitor cells: A key link between COPD and lung cancer?
This commentary focuses on two recent publications showing deregulation of the transcription factor Slug/Snail2 and TGF-β function in primary bronchial basal/progenitor cells of patients with Chronic Obstructive Pulmonary Disease (COPD) and the impact on proliferation and the expression of genes involved in stem cell maintenance. We discuss the molecular mechanisms related to the exhaustion of airway basal stem/progenitor cells in tobacco smoke-induced COPD, as well as putative links between COPD and lung cancer at the molecular level.
Considering Taguchi method as a feature selection method in agent-based models of cancer disease: A mini-review
Cancer biology involves complex dynamics and interactions between cells and the tissue environment. Mathematical modeling and computer simulation can provide a powerful instrument for considering this complexity. Agent-based modeling is a particular discrete hybrid modeling method.
The tumor dose sensitivity matrix and stem cells in head and neck cancer
Radiation therapy (RT) is one of the pillars of locally advanced head and neck cancer (HNSCC) treatment in combination with cisplatin or epidermal growth factor receptor inhibitors. Despite a very high local tumor control rate, approximately 50% of patients with locally advanced disease will develop a recurrence.
Genetic mutations in the molecular pathogenesis of gastrointestinal stromal tumor
Gastrointestinal stromal tumors are mesenchymal tumors which predominantly originate from the interstitial cells of Cajal in the intestinal lining. Around ~85% of malignant GISTs possess activating mutations in the tyrosine kinase receptors KIT or PDGFRA. The driver mutations in genes other than KIT or PDGFRA account for around 15% GISTs and belong to highly heterogeneous groups called wild-type GISTs. Around 20–40% of WT-GISTS are deficient for the succinate dehydrogenase complex (SDHA, SDHB, SDHC, SDHD).
Epigenetics of pediatric liver cancer and potential therapy
The pediatric liver cancer hepatoblastoma (HBL) has a complex etiology which is not yet determined. In contrast to adult liver cancer hepatocellular carcinoma (HCC), pediatric HBL has a low rate of genetic mutations suggesting that other mechanisms play a critical role in development of this disease.
BRCA1 and BRCA2 mutation variants in early breast cancer confer added prognostic information
Metastatic breast cancer to brain carries poor prognostic features with increased risks of occurrence in Tripple- negative and HER- positive breast tumors. In addition, tumors with mutated BRCA tumors, carry as well increased metastatic incidence. However, new clinical evidence suggest distinct clinical features between BRCA1 or BRCA2 mutated breast cancer and brain metastasis.
The role of MRI in detecting and characterizing brain metastases from breast cancer
Brain metastases are a feared complication of breast cancer, occurring in 15-25% of patients and being associated with poor prognosis and reduced quality of life. Magnetic resonance imaging (MRI) is an advanced technique that uses powerful magnetic fields and radio waves to produce detailed three-dimensional (3D) images of the brain's neuroanatomy and any potential pathology, especially in the management of brain metastases.
Identification and validation of N7-methylguanosine-associated gene NCBP1 as prognostic and Prognostic immune-associated biomarkers in breast cancer patients
Epigenetics is the study of heritable modifications to gene expression, such as DNA methylation, histone modifications, and RNA modifications, that do not alter the nucleotide sequence of the corresponding gene. Recently, RNA modification has emerged as a novel research focus.
Cancer-related anxiety, COVID-19, and the oncologist: the formation of a ‘Balint’ process group
The management of anxiety and distress in patients with cancer is stressful for the oncology clinicians who treat them. Unfortunately, psychosocial care for patients with cancer is not universally available or standardized. Referrals from oncology services to psychological serves are often not initiated early enough, may not be encouraged from medicine or surgical services, and are subsequently foregone or patients do not follow up beyond a single appointment.
Approach to testicular adrenal rest tumors in children and adolescents with congenital adrenal hyperplasia
Congenital adrenal hyperplasia (CAH) is a disorder affecting cortisol biosynthesis in the adrenal cortex [1]. 21-hydroxylase deficiency is the most frequent reason for CAH, with an incidence between 1:10.000 and 1:20.000 [2]. Due to the lack of enzyme function, patients with any enzyme deficiency cannot synthesize cortisol effectively.
CD133 and centrosomes: How CD133 inhibits autophagy and induces the undifferentiated state of cancer cells at centrosomes
CD133 is a transmembrane protein that mainly localizes to the plasma membrane of normal stem cells as well as cancer stem cells, and is widely known as a cancer stem cell marker. CD133 was recently shown to localize in the cytoplasm; however, its transport pathway and functions currently remain unknown.
The Oncogenic Role of ADAR1-Mediated RNA Editing in Thyroid Cancer
A-to-I RNA modifications performed by the adenosine deaminase acting on RNA (ADAR) protein family are gaining traction as important mechanisms in cancer biology. A-to-I RNA editing changes adenosine to inosine on double stranded RNA, which co-transcriptionally alters transcript sequence and structure. A number of microRNA (miRNA) precursors are known to be edited by the ADARs, which alters the expression and/or function of the mature miRNA.
Machine learning for precision medicine in cancer: Transforming drug discovery and treatment
Machine learning (ML) is a branch of artificial intelligence that uses an algorithm to process the data, retrieve valuable information, learn from it, find a pattern, and make predictions. Manual data analyses suffer from several disadvantages including it is time-consuming and subject to error.
A vicious cycle happened in the progress of hyperhomocysteinemia, the same may exist in the development of cancer
Homocysteine (Hcy) metabolism is at the intersection of two metabolic pathways: remethylation and trans-sulfuration, which abnormality can result in hyperhomocysteinemia (HHcy). In the past few years our team has been working on the molecular mechanism of HHcy development.